Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 558 participants.

Also called NCT05493163

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 558 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05493163
  • EU CT 2024-516144-25-00
  • EudraCT 2022-002218-18
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Czechia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05493163. Randomized; no masking; primary purpose treatment. Start 2022-10-19 (actual); primary completion 2026-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism
Acronym
PRAGUE-26
Intervention (Drug)
Thrombolytic
Intervention (Drug)
Standard anticoagulation
Lead sponsor
Faculty Hospital Kralovske Vinohrady (class: other government)
Collaborator
Charles University, Czech Republic (class: other)
Collaborator
University Hospital Ostrava (class: other)
Collaborator
University Hospital Olomouc (class: other)
Collaborator
Brno University Hospital (class: other)
Collaborator
St. Anne's University Hospital Brno, Czech Republic (class: other)
Collaborator
General University Hospital, Prague (class: other)
Collaborator
University Hospital Pilsen (class: other)
Collaborator
University Hospital Hradec Kralove (class: other)
Collaborator
University Hospital, Motol (class: other)
Collaborator
Hospital Pardubice (class: other)
Collaborator
Tomas Bata Hospital, Czech Republic (class: other)

Record details

Record id
cardio:ct-nct05493163
Content hash
a58d8b5778a013464311b1fd573a159739e58e0a85ed051bad9d9b14a64c92f7